SecBot SecBot
Biotech Drug Report Generated Nov 14, 2026

PLN-101095

PLRX·Pliant Therapeutics, Inc.
NEUTRAL
Drug Impact Rating3/10
Trial phase
Phase 1b
Time to market
At least 3-5 years away, if ever. The drug is still in Phase 1b testing. Even under a Fast Track pathway, it would need to complete Phase 2 and Phase 3 trials before any approval filing.
Why 3/10
No hard binary catalyst (PDUFA, pivotal readout, or AdComm) is scheduled in the next 12 months. PLN-101095 is in Phase 1b testing; the next catalyst would be further FORTIFY trial data updates, but no specific date has been announced. The drug is the company's lead asset after bexotegrast's failure, but its early stage caps the impact score.
Actionable Insight NEUTRAL

PLN-101095 is an early-stage oncology asset at a cash-strapped company that already lost its lead pipeline drug. Watch for FORTIFY enrollment completion updates and any efficacy signals from the Phase 1b expansion cohorts. The stock is trading near cash value, so positive data could drive a meaningful rally, but the company's financial runway and lack of analyst coverage are serious headwinds. No near-term binary catalyst is on the calendar.

Price Chart

Loading chart...

Executive Summary

PLN-101095 is an oral, small-molecule, dual-selective inhibitor of alpha-v-beta-8 and alpha-v-beta-1 integrins being developed by Pliant Therapeutics (PLRX) for ICI-refractory solid tumors. It is the company's lead asset after its former flagship drug bexotegrast failed in IPF, leading to a 45% workforce cut in 2025. PLN-101095 is in Phase 1b testing (FORTIFY trial) in combination with pembrolizumab, with Fast Track designation from the FDA. The stock trades near $0.70, close to its 52-week low, with overwhelmingly negative analyst sentiment (0 buy, 9 hold/sell) and major institutional holders exiting. The drug is too early-stage to support a bullish investment thesis, but the distressed valuation means any positive data could produce outsized returns.

How It Works

PLN-101095 is a pill that blocks two cell-surface proteins called integrins (alpha-v-beta-8 and alpha-v-beta-1). These integrins act like docking stations that tumors use to suppress the immune system and resist checkpoint inhibitor drugs like Keytruda (pembrolizumab). By blocking both integrins at once, PLN-101095 aims to re-sensitize tumors that have stopped responding to immunotherapy.

Trial Status

PLN-101095 is being studied in a Phase 1a/1b open-label trial (NCT06270706) combining it with pembrolizumab in patients with ICI-refractory advanced or metastatic solid tumors. The Phase 1a dose-escalation portion has completed, with interim data reported in March and December 2025 and updated at AACR in April 2026. The Phase 1b indication expansion trial, called FORTIFY, dosed its first patient in April 2026 and is actively enrolling. Preclinical proof-of-concept and clinical biomarker data were presented at SITC in November 2026. The FDA granted Fast Track designation in August 2026.

The Two-Sided Case

▲ Bull Case4
Novel mechanism: PLN-101095 is a first-in-class oral dual inhibitor of alpha-v-beta-8 and alpha-v-beta-1 integrins, targeting a key immune-suppression pathway that may re-sensitize checkpoint-refractory tumors. No approved drug targets this mechanism.
FDA Fast Track designation (August 2026) provides regulatory benefits including rolling NDA review and priority review eligibility, signaling FDA interest in the program.
FORTIFY Phase 1b trial is actively enrolling with strong enrollment per the company's November 2026 update, suggesting investigator and patient interest.
The stock trades near cash value (around $0.70, 52-week low $0.69), meaning much of the downside from the bexotegrast failure may already be priced in, and any positive data could produce an outsized move.
▼ Bear Case5
Very early stage: PLN-101095 is only in Phase 1b testing with no efficacy data from controlled trials yet. Most oncology drugs fail in Phase 2 or 3.
Company is financially distressed: Pliant cut 45% of its workforce in May 2025 after terminating its lead asset bexotegrast (IPF) due to safety issues. Q3 2026 net loss was $24.38M with limited cash runway.
Institutional exodus: Major holders JPMorgan (-84%), UBS (-82%), Invesco (-79%), and Morgan Stanley (-51%) all significantly trimmed or nearly exited their positions in Q3 2026.
Analyst sentiment is overwhelmingly negative: consensus shows 0 buy, 5 hold, 2 sell, 2 strong sell ratings. Coverage is stale (last analyst action March 2026).
Stock is at $0.697, near its 52-week low of $0.69, with a market cap likely under $50M, reflecting extreme investor pessimism and potential delisting risk.

Upcoming Catalysts

  • Further FORTIFY Phase 1b data readouts (date TBD)
  • Potential presentation at future medical conferences

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Pliant Therapeutics, Inc. PRESS-RELEASE PLRX ·Originating report

Sources · 7

Hover a chip for the title
1 morningstar.com2 markets.financialcontent.com3 nasdaq.com4 fiercebiotech.com5 seekingalpha.com6 morningstar.com7 sec.gov